Expert: GalNAc-conjugated small interfering RNA targeting hepatic LPA mRNA. Reduces Lp(a) synthesis by >95%. SC dosing Q12W. GalNAc moiety enables liver-specific uptake via ASGPR.

Everyday: Uses a tiny piece of genetic code (siRNA) to silence the gene that makes lipoprotein(a) in the liver. Lp(a) is an inherited form of bad cholesterol that you can't reduce with diet or statins — this drug literally turns off the gene.

Targets: ["LPA"]

Olpasiran - Elevated Lp(a) - OCEAN(a)-Outcomes CVOT 2027+

siRNA targeting Lp(a). OCEAN(a)-Outcomes CVOT fully enrolled but event accrual slower than expected — readout likely 2027+. If positive, first-in-class Lp(a) lowering with CV outcomes benefit. >95% Lp(a) reduction. SC Q12W dosing. Massive addressable market (~20% of population has elevated Lp(a)).